Ricoh 3D, Kallisio Ink Deal for Stentra Oral Stent for Radiation Oncology

Ricoh USA and Kallisio have begun a strategic partnership to manufacture and distribute Stentra, a U.S. Food and Drug Administration (FDA) 510(k)-cleared, patient-specific oral stent designed to improve radiotherapy for head and neck cancer (HNC).
 
Stentra was developed using technology that was exclusively licensed from MD Anderson Cancer Center. It protects healthy tissue during radiation therapy by displacing and immobilizing sensitive areas during treatment, allowing for more targeted and effective radiation delivery.
 
Ricoh 3D for Healthcare will leverage its network of FDA-registered 3D printing facilities to produce Stentra. This aims to provide rapid, efficient distribution to radiation oncology teams across the nation.
 
Beginning in October, radiation oncologists can order Stentra through Ricoh 3D for Healthcare’s clinical applications specialists.

 
“Our collaboration with Kallisio highlights our shared commitment to advancing cancer care by addressing critical needs in toxicity management,” said Gary Turner, Managing Director, RICOH 3D for Healthcare. “Stentra not only protects the tongue and other healthy tissues from exposure to radiation but also enhances the precision of radiation therapy, thereby reducing side effects and improving patient quality of life.”
 
Rajan Patel, CEO of Kallisio, added, “Partnering with RICOH 3D for Healthcare is a natural fit for our mission to transform cancer care. Ricoh’s expertise in advanced manufacturing and their robust distribution network, including point-of-care production capabilities and clinical applications team, make them an ideal partner. Together, we can ensure that Stentra™ reaches radiation oncology teams efficiently, enhancing treatment precision and patient outcomes on a broad scale.”
 
Earlier this year, Ricoh 3D and SimBioSys joined a collaborative initiative to explore technologies with the potential to aid in the treatment of breast cancer.